About 38% of rads surveyed said they had defended against at least one lawsuit, with such specialists at a higher risk than others in internal medicine. 

The publicly traded imaging center operator is teaming with Saint Alphonsus Health System to jointly run five facilities in Idaho. 

Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.

The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal. 

Some Omnipod 5 devices, manufactured by Insulet, are subject to the Class I recall. The products with the defect must be removed from where they are used or sold to ensure safety, as lower-than-expected insulin doses could have potentially lethal repercussions.